Institutional investors purchased a net $3.8 million shares of EBS during the quarter ended June 2016. This may signal that the smart money is gaining interest in this company as the 93.20% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ABERDEEN ASSET MANAGEMENT, INC. Bought 81.4 Thousand shares of Emergent BioSolutions Inc
LEGAL & GENERAL INVESTMENT MANAG... Bought 23.6 Thousand shares of Emergent BioSolutions Inc